Pharma Two B is a clinical-stage pharmaceutical company that is developing differentiated and value-added products, based on previously approved drugs. Our aim is to improve efficacy, safety and delivery profiles with the goal of increasing clinical value and decreasing the timeline to regulatory approval (US 505(b)(2)).
Our lead product candidate P2B001 is being investigated as treatment for early stage Parkinson’s disease (PD). P2B001 has shown remarkable results in phase II clinical trial (N=149 patients). Currently P2B001 is in phase III clinical trial. To learn more about the clinical performance of P2B001, please see: http://www.pharma2b.com/our-products/clinical-trials/
Pharma Two B is led by highly experienced team, supported by prominent scientific and clinical key opinion leaders, and backed by a dedicated group of investors.
Developing innovative products based on previously approved drugs, by maximizing the potential of their mechanism of action, adapting doses, delivery modes, and utilizing synergistic effects in combination products.